tiazofurin and Conjunctivitis

tiazofurin has been researched along with Conjunctivitis* in 1 studies

Other Studies

1 other study(ies) available for tiazofurin and Conjunctivitis

Article	Year
Phase I and pharmacokinetic study of tiazofurin (NSC 286193) administered by 5-day continuous infusion. Cancer chemotherapy and pharmacology, 1986, Volume: 16, Issue:2 A phase I and pharmacokinetic study of tiazofurin (NSC 286193), a C-nucleoside that inhibits IMP dehydrogenase, has been completed. The drug was administered by continuous infusion over 5 days. The maximum tolerated dose was 1650 mg/m2 per day, neurological toxicity being the dose-limiting factor. Gastrointestinal and hematological toxicity were mild. A definite relationship exists between dosage and steady-state levels. The plasma clearance was 29.13 (+/- SD 4.05) ml/min per m2. No complete or partial remissions were demonstrated among the 18 patients treated at five dose levels between 550 mg/m2 and 2200 mg/m2 per day. Topics: Adult; Chromatography, High Pressure Liquid; Conjunctivitis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Humans; Kinetics; Male; Middle Aged; Neoplasms; Neutropenia; Ribavirin; Ribonucleosides	1986

Article

Year

Phase I and pharmacokinetic study of tiazofurin (NSC 286193) administered by 5-day continuous infusion.

Cancer chemotherapy and pharmacology, 1986, Volume: 16, Issue:2

A phase I and pharmacokinetic study of tiazofurin (NSC 286193), a C-nucleoside that inhibits IMP dehydrogenase, has been completed. The drug was administered by continuous infusion over 5 days. The maximum tolerated dose was 1650 mg/m2 per day, neurological toxicity being the dose-limiting factor. Gastrointestinal and hematological toxicity were mild. A definite relationship exists between dosage and steady-state levels. The plasma clearance was 29.13 (+/- SD 4.05) ml/min per m2. No complete or partial remissions were demonstrated among the 18 patients treated at five dose levels between 550 mg/m2 and 2200 mg/m2 per day.

Topics: Adult; Chromatography, High Pressure Liquid; Conjunctivitis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Humans; Kinetics; Male; Middle Aged; Neoplasms; Neutropenia; Ribavirin; Ribonucleosides

1986